- Home
- VTGN vs ATOS Comparison
VTGN vs ATOS Comparison
Compare VTGN & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTGN
- ATOS
- Stock Information
- Founded
- VTGN 1998
- ATOS 2009
- Country
- VTGN United States
- ATOS United States
- Employees
- VTGN N/A
- ATOS N/A
- Industry
- VTGN Biotechnology: Pharmaceutical Preparations
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- VTGN Health Care
- ATOS Health Care
- Exchange
- VTGN Nasdaq
- ATOS Nasdaq
- Market Cap
- VTGN 82.7M
- ATOS 96.8M
- IPO Year
- VTGN N/A
- ATOS 2012
- Fundamental
- Price
- VTGN $2.15
- ATOS $0.74
- Analyst Decision
- VTGN
- ATOS Strong Buy
- Analyst Count
- VTGN 0
- ATOS 3
- Target Price
- VTGN N/A
- ATOS $7.13
- AVG Volume (30 Days)
- VTGN 128.0K
- ATOS 670.6K
- Earning Date
- VTGN 06-10-2025
- ATOS 05-12-2025
- Dividend Yield
- VTGN N/A
- ATOS N/A
- EPS Growth
- VTGN N/A
- ATOS N/A
- EPS
- VTGN N/A
- ATOS N/A
- Revenue
- VTGN $698,000.00
- ATOS N/A
- Revenue This Year
- VTGN N/A
- ATOS N/A
- Revenue Next Year
- VTGN N/A
- ATOS N/A
- P/E Ratio
- VTGN N/A
- ATOS N/A
- Revenue Growth
- VTGN N/A
- ATOS N/A
- 52 Week Low
- VTGN $1.90
- ATOS $0.55
- 52 Week High
- VTGN $5.00
- ATOS $1.81
- Technical
- Relative Strength Index (RSI)
- VTGN 40.55
- ATOS 57.95
- Support Level
- VTGN $2.00
- ATOS $0.59
- Resistance Level
- VTGN $2.14
- ATOS $0.67
- Average True Range (ATR)
- VTGN 0.16
- ATOS 0.06
- MACD
- VTGN 0.00
- ATOS 0.01
- Stochastic Oscillator
- VTGN 49.58
- ATOS 94.42
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.